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Protein aggregation is an important feature of neurodegenerative disorders. In Alzheimer's disease (AD)
protein aggregates are composed of hyperphosphorylated Tau and amyloid beta peptide (Ab). Despite the
involvement and identiﬁcation of the molecular composition of these aggregates, their role in AD
pathophysiology is not fully understood. However, depositions of these insoluble aggregates are typically
reported as pathogenic and toxic for cell homeostasis. New evidences suggest that the deposition of
these aggregates is a protective mechanism that preserves cell from toxic insults associated with the
early stages of neurodegenerative diseases. To better understand the biological role of the protein ag-
gregation with regard its effects in cellular homeostasis, the present study investigated the role of
insoluble Tau and Tau aggregates on crucial cellular parameters such as redox homeostasis, proteasome
activity and autophagy in hippocampal cell cultures and hippocampus of aged Lewis rats using a
rotenone-induced aggregation model. Neurons were exposed to rotenone in different concentrations and
exposure times aiming to determine the interval required for Tau aggregation. Our experimental design
allowed us to demonstrate that rotenone exposure induces Tau hyperphosphorylation and aggregation in
a concentration and time-dependent manner. Oxidative stress triggered by rotenone exposure was
observed with the absence of Tau aggregates and was reduced or absent when Tau aggregates were
present. This reduction of oxidative stress along with the presence of insoluble Tau was independent of
alterations in antioxidant enzymes activities or cell death. In addition, rotenone induced oxidative stress
was mainly associated with decrease in proteasome activity and autophagy ﬂux. Conversely, when
insoluble Tau appeared, autophagy turns to be overactivated while proteasome activity remained low.
Our studies signiﬁcantly advance the understanding that Tau aggregation might exert protective cellular
effects, at least brieﬂy, when neurons are facing neurodegeneration stimulus. We believe that our data
add more complexity for the understanding of protein aggregation role in AD etiology.
© 2016 The Authors. This is an open access article under the CC BY license (http://creativecommons.org/
licenses/by/4.0/).1. Introduction
Neurodegeneration is often associated with the presence of
extra and intracellular protein aggregates distributed throughout
the central nervous system (CNS). Several neurodegenerative dis-
orders, including Alzheimer's disease (AD) and frontotemporal
dementia, are characterized by the presence of intracellulare Biologia Evolutiva, Instituto
do Matao, 277, Cidade Uni-
ss article under the CC BY license (inclusions of neuroﬁbrillary tangles (NTFs) and paired helical ﬁla-
ments (PHFs). These inclusions are mainly composed of hyper-
phosphorylated Tau (Ross and Poirier, 2005; Frost et al., 2015).
Tau is a microtubule-associated phosphoprotein expressed pri-
marily in the CNS and mainly distributed at the axonal compart-
ment promoting microtubules assembly and stabilization.
Abnormal hyperphosphorylation of Tau at various sites negatively
regulates its function and is implicated in degeneration and
neuronal loss in AD and other tauopathies. Hyperphosphorylation
not only reduces Tau housekeeping functions but also increases its
cellular toxicity where in hyperphosphorylated Tau sequester the
normal Tau (Kuret et al., 2005) to form Tau oligomers, being thesehttp://creativecommons.org/licenses/by/4.0/).
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1996).
The presence of intracellular inclusions of Tau is believed to
disrupt neuron physiology, through alterations in microtubule dy-
namics (Kuret et al., 2005), axonal transport (Cuchillo-Ibanez et al.,
2008; Shahpasand et al., 2012; Smith and Bennett, 1997), synaptic
function (Scheff et al., 2013) and loss of redox homeostasis (Melo
et al., 2011). Proteasome and autophagy pathways, mechanisms
involved in clearing hyperphosphorylated Tau/Tau aggregates, are
also suggested to be dysregulated during the etiology of tauo-
pathies (Huang and Figueiredo-Pereira, 2010; Ben-Gedalya and
Cohen, 2012).
To date, several reports from animal and cellular models that
recapitulate the basic stages of disease progression suggested that
neuronal loss occurs before NFTs are formed. Tau oligomers that are
formed during the early stages of protein aggregation are consid-
ered to be more toxic to cells than protein inclusions themselves
(Chung et al., 2001; Flach et al., 2012; Hoover et al., 2010; Lasagna-
Reeves et al., 2010). Although Tau is implicated in the pathology of
AD, the contribution of few Tau species (oligomers and insoluble
Tau) in disease initiation are not fully appreciated. Studies also
report protective effects associated with the formation of protein
inclusions in AD (de Calignon et al., 2010; Sydow et al., 2011) and
other neurodegenerative diseases models (Bodner et al., 2006).
These ﬁndings emphasize the importance of studying cellular
events that occur prior and during the formation of protein ag-
gregation to advance our understanding of neurodegeneration
process in AD. Thus, although protein aggregation has been
extensively investigated, it biological role remains contradictory.
We hypothesize that this conundrum rises with the fact that most
reported studies have relayed on Tau overexpression or transgenic
systems expressingmutant Tau, lacking endogenous regulation and
possibly inducing extreme toxic environments distinctly from the
environment induced by constitutive protein aggregation.
We showed previously that low concentrations (0.5e1 nM) of
rotenone, a mitochondrial complex I inhibitor widely employed in
studies related to neurodegeneration (Radad et al., 2008; Ullrich
and Humpel, 2009), were able to induce hyperphosphorylation
and aggregation of constitutive Tau in the absence of cell death in
primary hippocampus cell cultures (Chaves et al., 2010). Chronic
administration of rotenone to rats also induces cerebral tauopathy
(H€oglinger et al., 2005; Almeida et al., 2016) revealing rotenone as a
reliable method to induce constitutive Tau aggregation in in vivo
and in vitro systems.
Based on this, rotenone exposure could be used, as a system to
indirectly evaluate whether dysfunctions in neuronal homeostasis
occur before the formation of Tau aggregation and whether Tau
aggregation inﬂuences positively or negatively these early
dysfunctions.
Oxidative stress induced by increase in reactive oxygen species
(ROS) is considered an early event occurring in AD, possibly acting
as an inductor of protein aggregation (Tabner et al., 2005; Hands
et al., 2011). In addition to oxidative stress, decrease in protein
degradation pathways, proteasome and autophagy, have been re-
ported during the initial stages of AD (Cecarini et al., 2007; Resende
et al., 2008).
Proteasome system plays a pivotal role in clearing oxidized and
misfolded proteins and inhibition of proteasome activity led to
increase in Tau accumulation (Tseng et al., 2008) and hyper-
phosphorylation (Agholme et al., 2014; Carrettiero et al., 2009).
Moreover, oxidative stress might impair protein degradation
pathways, such as the proteasome system (Cecarini et al., 2007;
Lam et al., 2000), and inhibition of proteasome activity can
induce oxidative stress (Maharjan et al., 2014) demonstrating a
cross-talk between both pathways in early phases of AD.Since exposure to high doses of rotenone (100 nM) disrupt
proteasome activity and increase ROS synthesis (Chou et al., 2010),
and rotenone exposure also induce Tau hyperphosphorylation, it is
plausible postulate that rotenone reproduce some early aspects
related with AD pathophysiology. Here, we propose investigate,
using hippocampal cell cultures and hippocampus of aged Lewis
rats, (1) whether dysfunctions in redox homeostasis, protein
degradation machinery and Tau hyperphosphorylation, triggered
by exposure to rotenone, occur before Tau aggregation; and (2)
whether dysfunctions induced by rotenone exposure in the
absence of aggregates are potentiated or mitigated by the presence
of insoluble Tau and Tau aggregates.
2. Experimental procedures
All the procedures were performed in strict accordance with
Institutional and International Guidelines for animal care and use
(Demers et al., 2006), as well as respecting the Brazilian federal law
11794/08 for animal welfare.
2.1. Primary neuronal cell culture and rotenone exposure
Methodology employed for cell culture was a modiﬁcation of
the previously described protocol (Kivell et al., 2001). Brieﬂy, 20
neonatal (1 day-old) Lewis rats had their brains dissected out to
access the hippocampus, which was dissociated in sterile cold so-
lution consisting of 120 mM NaCl, 5 mM KCl, 1.2 mM KH2PO4,
1.2 mM MgSO4, 25 mM NaHCO3, 13 mM glucose, pH 7.2. Cell so-
lution was centrifuged at 300  g for 5 min. The supernatant was
discarded and cells were suspended in Neurobasal A medium
(Gibco) supplemented with 0.25 mM Glutamax (Gibco), 2% B27
(Gibco), 0.25 mM L-Glutamine (Sigma) and 40 mg/L Gentamicin
(Gibco).
Cells were plated on 12-well nunclon (Nunc), 96-well plate
(Nunc) or confocal dishes (MatTek), coated with poli-D-lysine, at
the density of 1800 cells/mm2. Cultures were kept in a humidiﬁed
incubator with 5% CO2 at 37 C for nine days with the media
changed every three days.
It was previously reported that exposure of primary cell cultures
to rotenone in concentrations over 1 nM during 48 h induces
massive cell death (Chaves et al., 2010). However, exposure to low
concentration of rotenone (0.5 nM) during 48 h did not induce cell
death and triggered Tau aggregation. Here, to further investigate
rotenone effects in neuron homeostasis and in Tau aggregation,
exposure to 0.5 and 0.3 nM of rotenone were used. Exposure to
0.3 nM was chosen to verify whether lowering rotenone concen-
tration by 40% would impair its effects upon Tau aggregation.
Media were supplemented with rotenone (Sigma) 0.3 or 0.5 nM
or with dimethyl sulfoxide (DMSO, Sigma), and applied to cell
cultures during either 48 or 72 h. The concentration of DMSO was
maintained at 0.002% in all treatment groups. Cells plated on
confocal dishes were used for immunocytochemistry assays for
MAP2 and Tau detection and to live cell analysis of ROS content and
autophagy ﬂux. Cells grown on 6 and 96 wells culture plates were
used for western blot and biochemical assays.
2.2. Determination of cell viability by MTT reduction and trypan
blue stain assays
MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium
bromide) assay was carried on 96 wells plated neuronal cultures.
After each treatment, 20 ml of MTT (5 mg/ml) was added into each
well and the plate was further incubated for 1 h at 37 C. Media in
each well was discarded and the colored products of MTT in cells
were solubilized with 200 ml of DMSO. Optical intensity at 570 nm
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contained 6 independent measurements.
Trypan blue stain assay was performed adding 10 mL of Trypan
blue stain solution (Gibco) to cultured cells media at the end of
rotenone exposure time in order to stain in blue the cytoplasm of
cells with damaged plasma membrane. Immediately after the
addition of Trypan blue, cells were examined under an inverted
microscope (Nikon Eclipse TS100) using a 10 objective (100
magniﬁcation) and brightﬁeld images were acquired from three
different ﬁelds randomly choose per plate per each experimental
condition. Then, the number of Trypan blue positive cells per ﬁeld
was accessed.2.3. Detergent soluble and insoluble protein fractions
Total protein samples were extracted in microtubule destabi-
lizing conditions with modiﬁed RIPA buffer (50 mM Tris-HCl (pH
8.0), 150 mM NaCl, 1 mM EGTA, 1% Nonidet P-40, 0.25% sodium
deoxycholate, 0.1% SDS, 0.5% Triton X-100, 1 mM 4-(2-aminoethyl)
benzenesulfonyl ﬂuoride hydrochloride, 1 mg/ml protease inhibitor
cocktail (Sigma), 1 mMNaF, 1 mMNa3VO4), using homogenizer and
followed by incubation at 4 C for 30 min accordingly to a previ-
ously described method (Santa-Maria et al., 2007). Homogenates
were centrifuged at 20,000  g, 4 C, 30 min. Supernatant were
kept as soluble fraction and the pellet werewashed twice with lysis
buffer followed by centrifugation (20,000  g, 4 C, 30 min). The
total amount of protein present in the insoluble pellet was
extracted with equal volume of SDS sample buffer. Protein con-
centration from supernatant and insoluble fractions were deter-
mined using Bradford's reagent (Bradford, 1976).2.4. Immunoblot assays for total Tau and hyperphosphorylated Tau
detection
Proteins present in soluble and insoluble fraction were resolved
on 10% SDS-polyacrylamide gels, transferred to nitrocellulose
membrane and blocked (5% non-fat dry milk in TBS-T) during 1 h at
room temperature, then probed with primary antibodies.
Membranes were incubated overnight at 4 C with antibodies
against hyperphosphorylated Tau (1:1000, Sigma, Ser 199/202,
T6819, raised in rabbit), total Tau (1:1000, Sigma, T9450, raised in
mouse), and b-actin (1:1000, Santa Cruz, sc-47778, raised in
mouse). Membranes were washed with TBS-T (3X, 5 min) followed
by incubation with HRP conjugated secondary antibodies (anti-
rabbit 1:10000 (Amersham) or anti-mouse 1:6000 (Amersham))
during 1 h at room temperature. Blots were developed using ECL
reagent according to manufacturers instructions (PerkinElmer).2.5. Immunocytochemistry assays for hyperphosphorylated Tau and
MAP2 detection
Neurons were ﬁxed with methanol:acetone (1:1) for 10 min
at 20 C, rinsed with PBS and permeabilized with 0.2% triton X-
100 in PBS for 30 min. Non speciﬁc binding was blocked with 2%
normal goat serum and 4% BSA in PBS for 30 min and then incu-
bated overnight with primary antibodies against hyper-
phosphorylated Tau (1:1000, Sigma, Ser 199/202, T6819, raised in
rabbit) or MAP2 (1:1000, sc 74422; Santa Cruz, raised in mouse) in
1% NGS, 2% BSA and 0.2% triton X-100. Dishes were washed with
cold PBS followed by incubation with FITC or Texas red conjugated
secondary antibody for 2 h. Cells were mounted with mounting
medium containing DAPI (40,6-diamidino-2-phenylindole, Vector
laboratories).2.6. Proteasome activity
Proteasome activity was determined according to the previously
described method (Silva et al., 2012). Cells and brain tissue in each
treatment groupwere lysed in RIPA buffer, except for the absence of
protease inhibitor cocktail. Thirty micrograms of total protein were
incubated with 125 mM of the ﬂuorogenic substrate s-LLVY-MCA
(Calbiochem) in 20 mM Tris/HCl buffer, pH7.5, at 37 C. This sub-
strate is a standard peptide widely employed to speciﬁcally assess
the chymotrypsin-like proteasome activity, independent of ubiq-
uitination (Hanna et al., 2007). Fluorescence emissionwas recorded
at 440 nm (excitation at 365 nm) for 45 min in Gemini XPS Fluo-
rescence Microplate Reader.
2.7. Intracellular levels of ROS and hydrogen peroxide
Generation of ROS in live neurons was evaluated using the probe
CM-H2DCFDA (Invitrogen), according to a previously described
method (da-Silva et al., 2004). Brieﬂy, ROS levels were assessed by
incubating neurons 40 min with 2 mM of CM-H2DCFDA diluted in
cell culture media, followed by two rinses with phenol free Neu-
robasal A medium (Invitrogen) and immediately subjected to live
cell imaging analysis. Cells were imaged on Carl Zeiss LSM780
inverted Multiphoton microscope using an integrated live cell
chamber allowing the maintenance of a 5% CO2 and 37 C envi-
ronment, images were acquired from 3 ﬁelds, randomly chosen, for
each experimental condition. Experiment was performed in trip-
licates and the quantitative analysis performed using Image J (NIH)
as described previously (Figueiredo et al., 2013).
To evaluate the intracellular H2O2 content a modiﬁcation of
Zhou et al. (1997) method was employed. Brieﬂy, 30 mg of total
protein extract of cell cultures or brain tissue were incubated with
50 mM of the ﬂuorogenic reagent Amplex red (Molecular probes)
and 1.0 U/mL of Horseradish peroxidase diluted in 0.1 M of phos-
phate buffer, pH 7.0, at 37 C. Fluorescence emission was recorded
at 587 nm (excitation at 563 nm) for 10 min in Gemini XPS Fluo-
rescence Microplate Reader.
2.8. Protein carbonylation
Protein carbonylation levels in soluble fraction were measured
with Oxiselect Protein Carbonyl Immunoblot Kit (Cell Biolabs, Inc.,
San Diego, CA, U.S.). Fifteen micrograms of protein homogenates
were resolved by SDS-polyacrylamide gel and transferred to
nitrocellulose membranes. Membranes were then incubated with
DNPH solution for derivatization accordingly to manufacturers in-
structions, followed by blocking during 1 h at room temperature in
TBS-T with 5% non-fat dry milk. Blots were incubated with anti-b-
actin antibody and developed as previously described for
normalization.
Protein carbonylation was evaluated by incubating the mem-
branes with primary antibody against DNP (1:1000, 230801, Cell
Biolabs) in TBS-T with 5% non-fat dry milk during 1 h at room
temperature. Membranes were washed in TBS-T and incubated
with anti-goat horseradish peroxidase conjugated antibody diluted
1:1000 in solution containing 5% non-fat dry milk/TBS-T for 1 h at
room temperature. Labeling was developed with enhanced chem-
iluminescence reagent and the whole smear of bands per gel lane
considered for quantiﬁcation. Quantiﬁcation was done as already
detailed, using b-actin for data normalization.
2.9. Antioxidant enzymes assays
Catalase activity in cell homogenates was assayed following the
method described by Aebi (1984) bymonitoring the decomposition
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240 nm. Enzyme units were expressed as mmoles H2O2 decom-
posed/min/mg protein.
Glutathione peroxidase was assayed using commercial Kit
(Sigma) and enzyme activity was calculated based on the oxidation
of glutathione (GSH) to oxidized glutathione (GSSG). This is cata-
lyzed by Glutathione peroxidase coupled to the recycling of GSSG
back to GSH utilizing glutathione reductase and NADPH. The
decrease in NADPH absorbance measured at 340 nm during the
oxidation of NADPH to NADP is indicative of glutathione peroxidase
activity since the enzyme is the rate-limiting factor of the coupled
reactions. Results are expressed as mmoles of oxidized NADPH/mg
protein/min.
2.10. Autophagy ﬂux
Autophagy ﬂux was monitored expressing the LC3-eGFP-
mCherry construct (Kabeya et al., 2000; Kimura et al., 2007). The
expression of eGFP is restricted to autophagosomes and the
mCherry labeling can be found at the autophagosomes and auto-
phagolysosomes compartments. Autophagy ﬂux is the ratio be-
tween the number of vesicles presenting both ﬂuorescence emitted
by eGFP and mCherry, and the vesicles presenting only mCherry
signal (Castillo et al., 2013; Kimura et al., 2007; Nyfeler et al., 2011).
After 8 days of culture, cells were transfected with 1750 ng of
LC3-EGFP-mCherry using lipofectamine 2000 (Invitrogen), ac-
cording to manufacturer's protocol, followed by 48 h of 0.3 or
0.5 nM of rotenone exposure using phenol-free Neurobasal A cul-
ture medium. Three cells per dish from 5 different cultures were
evaluated at excitation wavelengths of 488 nm for EGFP and
535 nm for mCherry, and emission 520 nm and 620 nm, respec-
tively. Cells were imaged on Carl Zeiss LSM780 inverted Multi-
photon microscope using an integrated live cell chamber allowing
the maintenance of a 5% CO2 and 37 C environment. Quantitative
analysis of immunoﬂuorescence data was performed using Image J
(NIH) and the plug-in Green and Red puncta colocalization as
described previously (Pampliega et al., 2013). Autophagic ﬂux was
accessed according to Castillo and colleagues' protocol (Castillo
et al., 2013).
Autophagy was also monitored by western blot assays evalu-
ating LC3 II and Beclin-1 protein levels. Brieﬂy, western blot assays
were performed similarly to previously described herein, mem-
branes were incubated for 1 h at room temperature with anti-
beclin-1 (1:500, Santa Cruz, sc-11427, raised in rabbit) or over-
night with anti-LC3II (1/1000, Sigma L8918, raised in rabbit) and
developed as stated before.
2.11. Protein aggregation and oxidative stress in aged rats
Aged (12 months old) Lewis rats were anaesthetized with ke-
tamine and xylazine for subcutaneous insertion of osmotic mini-
pumps (Alzet). Minipumps were ﬁlled either with rotenone
dissolved in equal volumes of DMSO and polyethylene glycol (PEG,
Sigma, USA) which was delivered at the rate of 1 mg/kg/day or
2 mg/kg/day during 4 weeks, or only DMSO:PEG (1:1) as control.
After treatment animals were euthanized and their hippocampus
removed to analyze hyperphosphorylated and total Tau levels,
proteasome activity and intracellular hydrogen peroxide content.
For immunocytochemistry, rats were deeply anaesthetized and
perfused with saline (0.9%) followed by a ﬁxative solution consisted
of 4% paraformaldehyde (w/v) and 0.2% picric acid (v/v) in 0.1 M
PBS, pH 6.9, at 4 C. Hippocampus was removed and ﬁxed for
additional 90 min in ﬁxative solution described above, following
incubation in sucrose diluted in PBS for 48 h, sucrose was changed
every 24 h. Brain sections (14 mm) were obtained in a cryostat(Leica, CM3050, Germany), at 25 C. Sections were incubated for
24 h at 4 C with antibody against hyperphosphorylated Tau 1:200
(Santa Cruz; sc101813), followed by incubation with biotinylated
secondary antibody goat anti-rabbit immunoglobulin (1:230, Vec-
tor, USA) for 90 min. Sections were next incubated with avidin-
biotin peroxidase complex (1:120, Vectastain, Vector, USA) for
45 min and immunoreactivity was visualized using 3-30-dia-
minobenzidine tetrahydrochloride (DAB, Sigma) as chromogen and
H2O2 (0.05%) during 6 min of reaction. Following DAB reaction cells
were counterstained with hematoxylin and examined under mi-
croscope (Nikon Eclipse TS100) using 10 and 20 objectives,
images were acquired from three different ﬁelds randomly choose
per plate per each experimental condition for evaluation of the
staining proﬁle.
Hippocampus from aged rats exposed to 1 mg/kg/day of rote-
none or DMSO:PEG as the control, was removed for protein
extraction in order to evaluate hyperphosphorylation of Tau, pro-
teasome activity and H2O2 content, using the same methodology as
described earlier for cultured hippocampal cells.
2.12. Statistical analysis
Results were evaluated by one-way ANOVA followed by Tukey
post-test for cell culture analysis and Student's T-test for aged rat.
Statistics was assessed through GraphPad Prism (GraphPad Soft-
ware Inc., version 4.00, CA). A p-value 0.05 was considered to
indicate statistically signiﬁcant differences. It was employed a
minimum of n ¼ 3 for cell cultures and n ¼ 5 for animals. All ex-
periments were repeated at least twice and performed in technical
triplicates.
3. Results
3.1. Rotenone concentration and exposure time dictates whether
Tau hyperphosphorylation is accompanied or not by Tau
aggregation
Since Tau hyperphosphorylation is a crucial step for Tau aggre-
gation we quantitatively measured Tau hyperphosphorylated
levels. Soluble levels of hyperphosphorylated Tau normalized to
total Tau levels in hippocampal cultures revealed an increase by
60% and 35%, 48 h after exposure to 0.3 nM and 0.5 nM of rotenone,
respectively, as compared to DMSO (Fig. 1A).
To evaluate whether the observed increase in Tau hyper-
phosphorylated levels was sufﬁcient to trigger Tau aggregation, we
performed experiments measuring total Tau levels in detergent
insoluble protein fraction and immunocytochemistry assays to
detect Tau aggregation. Insoluble fraction analysis showed a sig-
niﬁcant increase by 45% in total Tau levels following exposure to
0.5 nM of rotenone during 48 h, strikingly exposure to 0.3 nM of
rotenone during the same period did not induce increase in Tau
total levels in the insoluble fraction (Fig. 1B).
Immunocytochemical labeling of hippocampal cultures showed
that immunoreactivity for Tau hyperphosphorylated is mainly
localized in the neurites and its raises as rotenone concentration
increase (Fig. 1C). In cells exposed to 0.5 nM of rotenone Tau
hyperphosphorylated staining tend to mainly localize towards the
cell body, illustrated by the increase in co-localization between
MAP2 and hyperphosphorylated Tau stains, suggesting Tau aggre-
gation in this cellular compartment (Fig. 1C).
Interestingly, DMSO exposed cells displayed smooth and elon-
gated labeling for microtubule associated protein 2 (MAP2),
although cell exposed to rotenone displayed puncta labeling,
probably indicating microtubule fragmentation triggered by Tau
hyperphosphorylation. Hyperphosphorylated Tau was also
Fig. 1. Quantitative analysis of Tau levels in cultured hippocampal cells exposed to DMSO, 0.3 or 0.5 nM of rotenone during 48 or 72 h. Hyperphosphorylated Tau normalized to
total-Tau in protein soluble fraction (A). Total Tau normalized to b-actin in protein insoluble fraction (B). Illustrative digital images of cultured hippocampal neurons labeled with
antibodies against hyperphosphorylated Tau (p-Tau) and MAP2 after exposure to rotenone (C). Dense p-Tau aggregates are found in neuronal (arrows) and non-neuronal (arrow
heads) cells exposed to 0.5 nM of rotenone during 48 h, as well as 0.3 nM of rotenone after 72 h. Values are shown as percent control (DMSO) ± S.D obtained from three independent
experiments. *p < 0.05, ***p < 0.001 as compared to DMSO; #p < 0.05, ##p < 0.01 compared as indicated, according to one-way ANOVA followed by Bonferroni ad-hoc test. Scale
bar ¼ 50 mm for low magniﬁcation and 10 mm for high magniﬁcation pictures in (C).
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0.5 nM of rotenone during 48 h (Fig. 1C).
Since the exposure to 0.3 nM of rotenone during 48 h induced
Tau hyperphosphorylation without triggering Tau aggregation, we
hypothesize that rotenone effect upon Tau aggregation in your
system could be also time-dependent. To evaluate our hypothesis
hippocampal cell cultures were exposed to 0.3 nM of rotenone
during 72 h and Tau hyperphosphorylation and aggregation were
evaluated.
Compared to exposure to 0.3 nM of rotenone during 48 h,
exposure for 72 h induced a 30% decrease in Tau hyper-
phosphorylated levels in the soluble fraction (Fig. 1A), being this
decrease accompanied by a 20% increase in total Tau levels in the
insoluble fraction (Fig. 1B). Immunocytochemistry assays in cells
exposed to 0.3 nM rotenone during 72 h demonstrated a clear shift
of Tau hyperphosphorylated staining from neurites only, as
observed in cells exposed to 0.3 nM of rotenone during 48 h and
controls, towards to a massive staining in neurons cell bodies and
other non-neuronal cells illustrating Tau aggregation.
Thus, rotenone triggers Tau hyperphosphorylation and aggre-
gation in a time and concentration-dependent manner (Fig. 1).
Accordingly with our ﬁndings we postulate that the concentration
and time dependence for the formation of Tau aggregation found inour model, allow us to mimic two different scenarios of Tau
dysfunction in the cultured neurons (Fig. 2).
The ﬁrst scenario is induced after exposure to 0.3 nM of rote-
none during 48 h and occurs before Tau aggregation, where only
Tau hyperphosphorylation is present in the cultured hippocampal
neurons. Since exposure to 0.3 nM of rotenone during 72 h triggers
Tau aggregation, this suggests that the early dysfunction observed
at 48 h precede and might trigger Tau aggregation at 72 h.
In the second scenario, during Tau aggregation, Tau hyper-
phosphorylation is accompanied with the formation of Tau aggre-
gates, being this scenario induced after exposure to 0.5 nM of
rotenone during 48 h or 0.3 nM of rotenone during 72 h. The fact of
Tau hyperphosphorylation levels, insoluble total Tau levels and
immunocytochemistry analysis did not differ between primary cell
cultures exposed to 0.5 nM of rotenone during 48 h or 0.3 nM of
rotenone during 72 h further support our rationale.3.2. Tau aggregation decreases the initial dysfunction in ROS levels
promoted by soluble hyperphosphorylated Tau
To validate our rationale we analyzed ROS synthesis in both
hypothetical scenarios. Oxidative stress is reported as a general
Fig. 2. Scheme illustrating time and dose-dependent effects of rotenone exposure over tau dysfunctions in hippocampal cell cultures. The exposure to 0.3 nM of rotenone during
48 h induces Tau hyperphosphorylation without triggering Tau aggregation, however at longer timer point (72 h) Tau aggregation is present, suggesting that the earlier dysfunction
observed at 48 h precedes and might trigger Tau aggregation at 72 h. Exposure to 0.5 nM of rotenone during 48 h triggers both dysfunctions in Tau homeostasis, hyper-
phosphorylation and aggregation, however faster than exposure to 0.3 nM of rotenone.
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suggested as additional generators of ROS.
In your model ROS content was signiﬁcantly higher by 40% after
exposure to 0.3 nM of rotenone during 48 hwhile in the presence of
protein aggregation (0.5 nM for 48 h or 0.3 nM for 72 h) we found a
signiﬁcant decrease in cellular ROS content as compared with the
scenario before Tau aggregation (Fig. 3). As expected, ROS level was
similar between primary cell cultures exposed to 0.5 nM of rote-
none during 48 h or 0.3 nM of rotenone during 72 h, illustrating the
reliability of our system.
Striking, our results suggest that the formation of Tau aggregates
decrease the initially increased ROS levels promoted by rotenone
exposure and provide evidences that ROS dysfunction occurs even
before the formation of Tau aggregates.3.3. Tau aggregation effects in oxidative stress are uncoupled from
alterations in the activity of antioxidant enzymes or cell death
Rotenone by deﬁnition is a classic inductor of oxidative stress,
thus we aimed to further verify if the presence of Tau aggregatesrestores or mitigates rotenone effects in other parameters of neu-
rons redox homeostasis. Since the exposure to 0.5 nM of rotenone
during 48 h triggered Tau aggregation at the same levels that
0.3 nM during 72 h, we chose to use the exposure to 0.5 nM of
rotenone during 48 h for the following analyses.
Protein carbonylation is a standard marker of oxidative stress,
evaluation of rotenone effect upon protein carbonylation levels
demonstrated an increase of 35% in neuronal cultures after expo-
sure to 0.3 nM as compared with DMSO-exposed cells, while in the
presence of Tau aggregates no signiﬁcant difference was found
(Fig. 4A). H2O2 is a classical upstream inductor of ROS, analysis of
H2O2 levels in our model detected that exposure to 0.3 nM of
rotenone increased H2O2 by 30% as compared to DMSO exposed
cells, supporting our previous ﬁndings with protein carbonylation
levels, the presence of Tau aggregates seems to mitigate rotenone
effects (Fig. 4B).
Together, our data strongly suggest that the presence of Tau
aggregates mitigated redox dysfunctions associated with rotenone
exposure in absence of Tau aggregates. We hypothesize that alter-
ation in the activity of antioxidant enzymes could be related with
Fig. 3. Illustrative confocal images of CM-H2-DCFDA staining in hippocampal primary cell cultures after rotenone exposure in the absence (0.3 nM during 48 h) and presence of Tau
aggregates (0.5 nM during 48 h and 0.3 nM during 72 h), and quantitation of CM-H2-DCFDA ﬂuorescence intensity among experimental groups. Values are shown as percent control
(DMSO) ± S.D obtained from three independent experiments. *p < 0.05, ***p < 0.001 as compared to DMSO; #p < 0.05, ###p < 0.001 compared as indicated, according to one-way
ANOVA followed by Bonferroni ad-hoc test. Scale bar ¼ 50 mm.
R.S. Chaves et al. / IBRO Reports 1 (2016) 32e4538our ﬁndings. Evaluation of antioxidant enzymes activity, mainly
glutathione peroxidase and catalase, demonstrated that enzymatic
activity remained unchanged after exposure to rotenone compared
with DMSO treated group (Fig. 4C and D). These ﬁndings suggest
that antioxidant enzymes are not induced to cope up with cellular
ROS generated following rotenone exposure or during Tau
aggregation.
Cell death assays were performed to role out whether the
identiﬁed decrease in redox homeostasis parameters was associ-
ated with cell death or decrease in cell viability. Both, MTT and
Trypan blue labeling assays illustrated the absence of cell death
followed by rotenone exposure associated or not with the presence
of Tau aggregates, suggesting that cell death is not associated with
the decrease of ROS levels related with rotenone effect in the
presence of Tau aggregates (Fig. 4E and F).3.4. Decreased autophagy ﬂux triggered by rotenone is rescued by
the presence of Tau aggregates
We hypothesized that the lack of ROS induction in the presence
of Tau aggregates could be related with an up-regulation in the
activity of protein degradation pathways such as autophagy and
proteasome.
Impairment of protein degradation pathways is suggested as
crucial towards the formation of protein aggegates and the artiﬁcial
activation of these pathways can delay or even repair dysfunctions
induced by protein aggregates in neurodegenerative diseases. To
investigate the role of autophagy in the formation of Tau aggregates
in our system, we evaluated autophagy ﬂux after exposure to
rotenone in the absence and presence of Tau aggregates.
Fig. 4. Oxidative stress and cell viability after rotenone exposure in the absence (0.3 nM during 48 h) and presence of Tau aggregates (0.5 nM during 48 h). Protein carbonyls levels
after exposure to rotenone, whole lanes were considered for density quantiﬁcation (A). Measurement of H2O2 levels (B) and Glutathione peroxidase (GPx) (C) and Catalase (D)
enzymatic activity. Cell viability was evaluated by MTT reduction (E) and Trypan blue labeling (F). Data are shown as percent of control (DMSO) ± S.D. or mean ± S.D. obtained from
three independent experiments. *p < 0.05; **p < 0.01 as compared to DMSO according to one-way ANOVA followed by Bonferroni ad-hoc test. Scale bar ¼ 100 mm.
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illustrated an increase in the number of autophagolysosomes ves-
icles without detectable changes in the number of autophagosomes
vesicles. The analysis of autophagic ﬂux in these cells revealed a
20% decrease in autophagic ﬂux, supporting the increase in the
number of autophagolysosomes vesicles and demonstrating a
reduction in autophagy process (Fig. 5A). Meanwhile, in the pres-
ence of Tau aggregates rotenone exposure did not alter the number
of autophagolysosomes or autophagosomes vesicles but did induce
a massive increase in autophagy ﬂux (Fig. 5A).
To determine how autophagy is affected, we evaluated the levels
of LC3 II and Beclin-1 key proteins involved in autophagy process by
western blot. Exposure to 0.3 nM of rotenone for 48 h induced 40%
increase in LC3 II levels indicating failure in the autophagy process
since increases in LC3II indicate accumulation of autophagolyso-
somes and autophagosomes, exposure to 0.5 nM did not induce
changes in LC3 II levels (Fig. 5B). Beclin-1 expression levels before
and during Tau aggregation did not show alteration (Fig. 5C), sug-
gesting that nucleation of autophagic vesicles seems to be pre-
served during protein aggregation, and reinforcing that fusion of
autophagic vesicles and lysosomes might be impaired.We complemented our analysis of degradation pathways eval-
uating proteasome proteolytic activity. Exposure to rotenone
independently of the presence or absence of Tau aggregates
signiﬁcantly reduced proteasome activity by 20% and 10%, respec-
tively when compared with DMSO-exposed cells (Fig. 5D).
Thus, we identiﬁed that autophagy is modulated differently
when rotenone exposure induces Tau aggregates thanwhen it does
not, while proteasome activity is reduced in both conditions.
Interestingly, our data suggest that the formation of Tau aggregates
normalizes or mitigates cellular dysfunctions detected in the
absence of them (Fig. 6), suggesting a possible protective effect
associated with the formation of Tau aggregates.
3.5. H2O2 levels and proteasome activity are disrupted
independently of Tau aggregation in the hippocampus of aged rats
Rotenone can also promote Tau hyperphosphorylation and ag-
gregation in a time and concentration- dependent manner in aged
rats resembling our experimental protocol for hippocampal cell
cultures (Almeida et al., 2016). Then to further expand our ﬁndings,
we evaluated whether parameters such as H2O2 levels and
Fig. 5. Autophagy ﬂux and proteasome activity in hippocampal cultures after rotenone exposure in the absence (0.3 nM during 48 h) and in presence of Tau aggregates (0.5 nM
during 48 h). Illustrative confocal images of LC3-eGFP-mCherry expression in hippocampal neurons following DMSO or rotenone exposure. Quantiﬁcation of GFP and mCherry
positive vesicles per the total amount of vesicle identiﬁed per cell and the evaluation of the autophagy ﬂux in LC3-eGFP-mCherry transfected neurons (A). LC3II (B) and Beclin-1 (C)
levels normalized to beta-actin in culture cells exposed to DMSO or rotenone. Proteasome activity analysis after exposure to DMSO or rotenone (D). Values are shown as percent
control (DMSO) ± S.D obtained from three independent experiments. *p < 0.05; **p < 0.01; ***p < 0.001; as compared to DMSO according to one-way ANOVA followed by
Bonferroni ad-hoc test. Scale bar ¼ 30 mm.
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aggregates in the hippocampus of aged rats.
Aged rats exposed to 1 mg/kg/day of rotenone did not show
intracellular hyperphosphorylated Tau inclusions in hippocampus,
however with exposure to 2 mg/kg/day of rotenone we identiﬁed
dense intracellular hyperphosphorylated Tau immunolabeling
(Fig. 7A), although we were not able to infer about the morphology
or distribution of this aggregates inside of stained cells. Accordingly
with this result we selected the exposure to 1 mg/kg/day of rote-
none as possible candidate to evaluate parameters inﬂuenced by
rotenone exposure in the absence of Tau aggregates.
As expected, exposure to 1 mg/kg/day induced 10% increase in
Tau hyperphosphorylated levels in hippocampus as compared to
age-matched DMSO-exposed rats (Fig. 7B), illustrating Tau
dysfunction independently of the presence of aggregates. In the
absence of Tau aggregates, these aged rats also presented a signif-
icant decrease of 10% in proteasome activity and an increase, of the
same magnitude, in H2O2 levels (Fig. 7C and D, respectively).
Identify the same pattern of dysfunction observed in vitro using
an in vivo model strengths our results and suggests that the samearray of rotenone induced dysfunctions that trigger Tau aggregation
in vitro might happen in vivo as well.4. Discussion
Here we have shown that exposure to rotenone promotes Tau
hyperphosphorylation and aggregation, dysfunctions in redox ho-
meostasis and decrease in the activity of protein degradation
pathways, all in the absence of cell death and before it triggers Tau
aggregation. We also found that the formation of Tau aggregates
mitigates most dysfunctions initially triggered by rotenone expo-
sure, suggesting that Tau aggregation might exert protective
cellular effects, at least brieﬂy, when neurons are facing neuro-
degeneration stimulus.
In our previous study, we showed that exposure to rotenone
(1 nM) can induce Ab and alpha-synuclein aggregation in hippo-
campal cell cultures, however Tau aggregation required 50% less
rotenone to be triggered (0.5 nM), suggesting that rotenone effect
upon Tau aggregation is stronger and take place early than Ab and
a-synuclein aggregation. Furthermore, our group also found that in
Fig. 6. Summary of results achieved in the present study. Note that the formation of Tau aggregates mitigates most dysfunctions initially triggered by rotenone exposure. Rot:
Rotenone, p-Tau; Hyperphosphorylated and GPx: Glutathione peroxidase.
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none during 4 weeks, Tau hyperphosphorylation and aggregation is
detected in the absence of a-synuclein dysfunction supporting our
data (Almeida et al., 2016). In this study, we extend our under-
standing of Tau pathology analyzing the interplay between oxida-
tive stress and protein degradation pathways during the
progression of Tau aggregation.
Events that precede cellular loss are important for determining
disease etiology. In this study, results from in vivo and in vitromodel
suggest that early cellular alterations related with neurodegener-
ative processes occur earlier than Tau aggregation. Although, the
real cause and consequence of protein aggregation in neurode-
generative diseases remains controversial (Congdon and Duff,
2008), the presence of intracellular Tau aggregates may be of
relevance during neurodegenerative disease pathophysiology
(Flach et al., 2012).
Tau hyperphosphorylation is considered the primary event in
Tau dysfunction in AD progression. In this study we found that,
exposure to low concentration of rotenone (0.3 and 0.5 nM)
increased Tau hyperphosphorylation in hippocampal neurons as
analyzed by antibody speciﬁc for Ser199/202 epitopes through
immunocytochemistry and immunoblot assays. Activation of many
kinases can trigger Tau phosphorylation of which glycogen syn-
thase kinase-3b (GSK3b), MAPK and JNK have been shown to play a
part in AD progression (Pei et al., 2001).
Rotenone induced hyperphosphorylation of Tau is suggested to
be induced by the activation of GSK3b (Hongo et al., 2012) and
occurs at a large number of phosphorylation sites (Ser 396, S202/
T205, T212/S214 and S396/S404) (Han et al., 2014; H€oglinger et al.,
2005). These ﬁndings support our credence of using rotenone at
low concentration as a model to study Tau pathology.
In the presents study, although increased hyperphosphorylated
Tau was evident following exposure to 0.3 and 0.5 nM of rotenone
for 48 h, Tau aggregates in the insoluble fraction were only iden-
tiﬁed in cells exposed to 0.5 nM of rotenone. However, neuronalcultures exposed to 0.3 nM of rotenone for prolonged period (72 h)
also displayed Tau aggregation, suggesting that the earlier dys-
functions observed (at 48 h) might trigger Tau aggregation at later
time points (72 h). Our ﬁndings suggested that we could take
advantage of rotenone's effect been dose and time-dependent to
evaluate whether the formation of Tau aggregates could further
increase dysfunctions already triggered by rotenone exposure.
Thus, since the occurrence of ROS dysfunctions following rote-
none exposure is well described (Dukes et al., 2005; Sherer et al.,
2003) and evidences suggest that accumulation of insoluble and
phosphorylated Tau in neurodegenerative diseases is a toxic event
compromising neuronal function through the induction of ROS and
impairment of protein clearance machinery (Ciechanover and
Brundin, 2003). We tested in your system whether the formation
of Tau aggregates could further increase ROS synthesis triggered by
rotenone exposure, surprisingly exposure to rotenone in the pres-
ence of Tau aggregates did not elicited further increase in ROS
synthesis but returned ROS levels to levels similar to control cell
cultures.
It is well known that cells can cope with oxidative stress by
inducing antioxidant response, to role out whether the formation of
Tau aggregates activated antioxidant pathways leading to decrease
in ROS synthesis the activity of antioxidant enzymes were
measured. The evaluation of antioxidant enzymes activity did not
reveal any signiﬁcant changes associated with rotenone exposure,
suggesting that the observed decrease in ROS, protein carbonyla-
tion and H2O2 following Tau aggregation is due to the activation of
secondary antioxidant pathways.
Our results raised two interesting observation, (i) that rotenone
exposure triggers Tau hyperphosphorylation simultaneously with
increases in ROS synthesis, (ii) with the formation of Tau aggregates
the initially triggered increase in ROS synthesis is buffered by a
pathways independent of changes in the activity of antioxidant
enzymes.
Fig. 7. Tau hyperphosphorylation, Tau aggregation, H2O2 levels and proteasome activity in the hippocampus of aged rats after rotenone exposure. Representative digital images
showing hyperphosphorylated Tau immunoreactivity and illustrating Tau inclusions after exposure to 2 mg/kg/day of rotenone (A). Quantitative analysis of hyperphosphorylated
Tau (p-Tau) levels normalized to total-Tau in the hippocampus of aged rats exposed to DMSO or 1 mg/kg/day (B). Proteasome activity (D) and measurement of H2O2 levels (E) in the
hippocampus of aged rats exposed to rotenone in the absence of Tau aggregates. Data are shown as percent of control (DMSO) ± S.D.; n ¼ 5 for each experimental group; **p < 0.01
as compared to DMSO according to Student's T-test. Scale bar ¼ 100 mm.
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strated with the presence of increased malondialdehyde, 4-
hydroxynonenal (Lovell et al., 1995) and protein carbonyls (Ken-
neth Hensley et al., 1995; Hensley et al., 1996) in brain and cere-
brospinal ﬂuid. Growing evidences also show that oxidative stress
is increased in Tau transgenic mice (David et al., 2005; Rhein et al.,
2009) and that reduction of antioxidant enzymes increase even
more Tau hyperphosphorylated levels in these mice (Murakami
et al., 2011) suggesting that Tau hyperphosphorylation is possibly
linked to dysfunctions in redox homeostasis.
Evidences also have shown up-regulation of Tau kinases as
GSK3b and p38 MAPK under oxidative stress conditions in different
in vitro systems (Goedert et al., 1997; Feng et al., 2013). In your
system possibly rotenone effect upon ROS synthesis could be
related with its capability to induce Tau hyperphosphorylation,
however further experiments need to be done employing antioxi-
dant compounds following rotenone exposure to evaluate this
hypothesis.
Protein degradation mechanisms are the ﬁrst line of defense
against the formation of protein aggregates and evidences suggest
the disruption of ubiquitin proteasome system (Keller et al., 2000;
Carrettiero et al., 2009) and autophagy (Wolfe et al., 2013) in AD.
We hypothesized that rotenone effects upon Tau aggregation in
your system could be related with dysfunctions in proteasome
proteolysis activity or autophagy process possibly triggered byrotenone induced ROS synthesis. We observed a signiﬁcant decline
in proteasomal activity associated with increased oxidative stress
parameters following exposure to rotenone in the absence of Tau
aggregates. Therefore, following rotenone exposure and in the
presence of Tau aggregates we found decreased proteasome ac-
tivity uncoupled to dysfunctions in oxidative stress parameters.
Impairment of proteasome activity as a result of oxidative stress has
been shown earlier in HEK and SK-N-MC cells following 100 nM of
rotenone exposure (Chou et al., 2010). Our ﬁndings partially rein-
force this association, since we also found decreased proteasome
activity in the absence of oxidative stress.
Proteasome activity is tightly connected to autophagy process
and impairment of proteasome activity can induce increase in
autophagy process (Ge et al., 2009). In our system we observed
notable increase of LC3II levels and autophagolysosomes accumu-
lation following exposure to 0.3 nM of rotenone suggesting auto-
phagy impairment (Mizushima and Yoshimori, 2007) in the
absence of protein inclusions, which may be of relevance to trigger
protein aggregation (Zhang et al., 2013).
Interesting, our data demonstrate that both autophagy and
proteasomal impairment occur before Tau aggregation in your
system probably contributing with Tau aggregation at late time
points. It has been stated earlier that GSK3b activation by rotenone
triggers Tau hyperphosphorylation and also impair of lysosomal
acidiﬁcation possibly reducing autophagy ﬂux (Avrahami et al.,
R.S. Chaves et al. / IBRO Reports 1 (2016) 32e45 432013). On the contrary, Inhibition of GSK3b is shown to ameliorate
autophagic degradation (Parr et al., 2012). From the present study it
is evident that rotenone exposure effects could be due to GSK3b
activation, suggesting GSK3b as possible target to impair rotenone
effects upon Tau dysfunction.
The presence of Tau aggregates associated with increased
autophagy ﬂux in your system possibly explaining the lack of ROS
dysfunction in the presence of these aggregates. Since evidences
suggest that autophagy activation can decrease ROS levels
(Filomeni et al., 2015) and increase in ROS synthesis is a potent
inducer of autophagy mechanism (Filomeni et al., 2010; Lee et al.,
2012).
In rats, although the in vivo systemmay differ from cell cultures,
the increase in Tau hyperphosphorylation is induced accompanied
by increased hydrogen peroxide levels and a decreased proteasome
activity in hippocampus, which corroborates with cell cultures re-
sults and indicates that proteasome dysfunction and oxidative
stress may be the ﬁrst signals of cell impairment triggered by
rotenone exposure before Tau aggregation.
Together our results highlight the capability of rotenone expo-
sure mimic dysfunction related with the early stages of AD possibly
by enhancing ROS synthesis and suggest overall decrease in neuron
environment toxicity, measured by protein carbonyls, H2O2 levels
and Tau hyperphosphorylation, following the formation of Tau
aggregates.
The decrease in toxicity following Tau aggregation suggest a
possible protective effect of protein aggregation mediated by
autophagy that could reduce hyperphosphorylated Tau oligomers
preventing further cell impairments (Alonso et al., 2006), at least
during the temporal window experimentally analyzed in your
work. However, it remains to be addressed for how long these
protective effects remain active and why they fade allowing the
neurodegeneration occurs in late stages of AD and other
tauopathies.
5. Conclusion
In conclusion this study demonstrated the presence of Tau
hyperphosphorylation associated with decrease in proteasome
activity and autophagic ﬂux, as well as increase in oxidative stress,
precede the formation of Tau aggregates and that during the initial
phase of protein aggregation, oxidative parameters seem to return
to basal levels revealing a possible protective mechanism, possibly
acting through autophagy induction. The cause and effect relation
between Tau aggregation, redox homeostasis dysfunctions and al-
terations in protein degradation pathways following rotenone
exposure remain to be elucidated.
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